Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 776 matching trials from the live ClinicalTrials.gov search.
Conditions
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Real Acupressure Band, Placebo Acupressure Band
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
4 Years to 18 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
24
States / cities
Long Beach, California • Los Angeles, California • Hartford, Connecticut + 20 more
Conditions
Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation
Other · Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 1 more
Conditions
Sarcoma, Neuroblastoma, Wilm's Tumor
Interventions
Tumor lysate-pulsed dendritic cell (DC) vaccine, Hematopoietic stem cell transplantation (HSCT)
Biological · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more
Conditions
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Interventions
Zilovertamab vedotin
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 25 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 14 more
Conditions
Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory
Interventions
Abemaciclib
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 25 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Atlanta, Georgia
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
Interventions
Melphalan
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma, DIPG Brain Tumor
Interventions
Eflornithine (DFMO), AMXT 1501 Dicaprate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 26 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 11 more
Conditions
Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
Interventions
Nivolumab, EKG, MRI Brain and/or spine, Body CT Scan, MDASI-BT, MDASI-SP
Drug · Diagnostic Test · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Houston, Texas
Conditions
Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma
Interventions
Silmitasertib, Irinotecan, Temozolomide, Vincristine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more
Conditions
Pancreatic Neuroendocrine Tumors (pNET)
Interventions
BEZ235, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Lexington, Kentucky + 1 more
Conditions
Neuroblastoma, Ganglioneuroblastoma
Interventions
Proton Beam Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Months to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neuroblastoma
Interventions
propofol, ropivacaine, Wong-Baker FACES® Pain Rating Scale, Post-procedural quality of life (QOL)
Device · Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Study of MLN8237 in Combination With Irinotecan and Temozolomide

NCT01601535
Conditions
Neuroblastoma
Interventions
MLN8237, Irinotecan, Temozolomide
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
12 Months to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
valproic acid
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
15
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
Conditions
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions
OPT-821 (QS-21), oral β-glucan
Biological · Dietary Supplement
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
14 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
4
States / cities
Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Conditions
Brain Tumor Recurrent
Interventions
Methotrexate, Etoposide, Ommaya Reservoir
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, sargramostim, cyclophosphamide, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
2
States / cities
Paterson, New Jersey • New York, New York
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Temsirolimus, Valproic Acid
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina
Conditions
Refractory Brain Tumors
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

High-Risk Neuroblastoma Chemotherapy Without G-CSF

NCT02786719
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Etoposide, Vincristine, Doxorubicin, Sargramostim
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Months to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Conditions
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
cixutumumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Months to 30 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
93
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Conditions
Neuroblastoma
Interventions
Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin, Autologous Stem Cell Infusion, Granulocyte colony stimulating factor
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota